How Revance Therapeutics, The IBD 50's No. 1 Stock, Is Taking On 'Prestige' Medical Aesthetics

How Revance Therapeutics, The IBD 50's No. 1 Stock, Is Taking On 'Prestige' Medical Aesthetics

Revance Therapeutics and RVNC stock are in rarified positions after the FDA approved the company's new treatment for frown lines.